Introduction
============

A complex network of genes are required for maintaining the cellular homeostasis in colorectal tissue. In the original multistep progression model of colorectal cancer (CRC) first proposed by Vogelstein et al, normal colonic epithelium gets transformed into benign (adenoma) neoplastic epithelium followed by full blown invasive cancer and eventually metastasis \[[@B1]\]. Over the years, significant advances in molecular genetics and caner biology have led to the understanding that there exist 3 distinct molecular phenotypes of CRC: (1) chromosomal instability(CIN) \[[@B2]\]; (2) microsatellite instability(MSI) \[[@B3]\]; and (3) the recently discovered sessile and traditional serrated adenomas, a subset of hyperplasic polyps that progress to serrated carcinomas \[[@B4]\].

Some of the key signaling pathways implicated in colorectal carcinogenesis are Epidermal Growth Factor Receptor Signaling (EGFR) pathway, WNT signaling \[[@B1]\] and transforming growth factor-β (TGF β) signaling \[[@B5]\]. Translational research has resulted in the bench-to-bedside application of biomarkers like *KRAS*, *BRAF* and PI3K for personalized medicine \[[@B6]\]. One of the key determinants of response to panitumumab and cetuximab therapy in colorectal cancer is the presence of mutations in the *KRAS* gene \[[@B7],[@B8]\]. Testing for certain "activating" mutations in the *KRAS* gene is currently one of the most widely employed methods to predict responsiveness to EGFR inhibitors. Patients with presence of *KRAS* mutations in their tumors do not respond to EGFR inhibitors. On the other hand, a significant proportion of CRC patients with the wild-type (normal) *KRAS* gene fail to respond to EGFR inhibitors and mutations in other genes such as *PIK3CA/BRAF/NRAS/PTEN/TP53* have been implicated for resistance in this subgroup of patients \[[@B7]-[@B9]\]. *BRAF* mutations are known to be mutually exclusive with *KRAS* mutations and Vaughn et al have reported that almost 8% of the CRC subgroup with wild type *KRAS* gene had *BRAF* mutations; these patients would receive EGFR inhibitors but would be unresponsive to therapy \[[@B8]\].

Constitutive activation of the mitogen-activated protein kinase (MAPK) pathway regulates cellular proliferation, differentiation, and death. Oncogenic mutations in the v-Raf murine sarcoma viral oncogene homolog B1 (*BRAF)* in CRC were first described by Davies et. al and the commonest mutation was a single phosphomimetic substitution in the kinase activation domain (V600E) that led to activation of the MAPK pathway \[[@B10]\] Although *BRAF* mutations have been identified in a variety of cancers, their highest incidence to the tune of almost 60% is seen in melanomas \[[@B10]\]. The CRC subset that originates from advanced serrated polyps have a distinct molecular phenotype characterized by widespread hypermethylation of CpG islands in the promoter regions of genes, referred to as the CpG island methylator phenotype (CIMP) \[[@B11]\], microsatellite instability (MSI) and oncogenic mutations in *BRAF* gene \[[@B4],[@B12],[@B13]\]. Testing for *BRAF* mutation is beneficial in judicious selection of patients for targeted therapy \[[@B8],[@B9]\] and also a cost effective approach in the HNPCC (Hereditary Non-polyposis Colorectal Cancer) workup; presence of *BRAF* mutation with absence of MLH1 protein is indicative of sporadic CRC \[[@B14],[@B15]\].

In this study we comprehensively investigated the incidence of *BRAF* mutations in Saudi CRC and its clinico-pathological correlation, its association with molecular markers and overall survival.

Materials and methods
=====================

Patients' selection and TMA construction
----------------------------------------

A total of 770 patients with CRC diagnosed between 1990 and 2011 were randomly selected from King Faisal Specialist Hospital and Research Centre (KFSHRC), and Security Forces Hospital (SFH), Riyadh. A colorectal tissue microarray was constructed comprising of 770 CRC samples as described previously \[[@B16]\]. Clinical and histopathological data were available for all these patients. Patients with colon cancer underwent surgical colonic resection and those with rectal cancer underwent anterior resection or abdominoperineal resection. All node-positive colon cancers received 5-fluorouracil-based adjuvant chemotherapy. A vast majority of the rectal cancers received radiotherapy alone or chemoradiotherapy prior to surgery, followed by adjuvant chemotherapy after surgery. Colorectal Unit, Department of Surgery (KFSHRC and SFH), provided long-term follow-up data about the date and cause of death for this cohort of patients. Follow-up was calculated from the date of resection of the primary tumor, and all surviving cases were censored for survival analysis on 31st December 2011. Two pathologists (P.B., S.P.) reviewed all tumors for grade and histological subtype. The institutional review board of the King Faisal Specialist Hospital and Research Centre approved the study.

DNA isolation
-------------

DNA was extracted from paraffin-embedded CRC tissues using Gentra DNA isolation kit (Gentra, Minneapolis, MN, USA) following the manufacturer's recommendations as described previously \[[@B17]\].

PCR and DNA sequencing for *KRAS* and *BRAF* gene
-------------------------------------------------

*KRAS* and *BRAF* mutation analysis was performed on 755 and 757 CRC samples respectively. Primer 3 software was used to design the primers for Exon 15 of *BRAF*; Exon 1, 2 of *KRAS* (Table  [1](#T1){ref-type="table"}). The PCR sequencing protocol was same as described earlier \[[@B17]\]. The samples were finally analyzed on an ABI PRISM 3100xl genetic analyzer (Applied Biosystems, Foster City, CA).

###### 

**Primer sequence of*BRAF*and*KRAS*gene**

  **Exon**     **Forward primer**           **Reverse primer**
  ------------ ---------------------------- --------------------------
  ***BRAF***                                 
  Exon 15      TGCTTGCTCTGATAGGAAAATG       AGCATCTCAGGGCCAAAAAT
  ***KRAS***                                 
  Exon 1       TTAACCTTATGTGTGACATGTTCTAA   AGAATGGTCCTGCACCAGTAA
  Exon 2       CCAGACTGTGTTTCTCCCTTC        TTTAAACCCACCTATAATGGTGAA

Microsatellite markers and analyses
-----------------------------------

Allelic imbalances were measured by performing microsatellite analysis on all matched normal and tumor tissue by PCR amplification. A reference panel of five pairs of microsatellite primers, comprising two mononucleotide microsatellites (BAT25, BAT26) and three dinucleotide microsatellites (DS123, D5S346 and D17S250) were used to determine tumor MSI status \[[@B3]\]. Multiplex PCR was performed in a total volume of 25 μl using 50 ng of genomic DNA, 2.5 μl 10 × Taq buffer, 1.5 μl MgCl2 (25 mM), 10 pmol of fluorescent-labeled primers, 0.05 μl dNTP (10 mM) and 0.2 μl Taq polymerase (1 Uμl − 1; all reagents were from Qiagen Inc., Valencia, CA, USA). PCR was performed using an MJ Research PTC-200 thermocycler. The samples in which the novel alleles were found at one, and two or more of those five loci were assigned MSI-L and MSI-H respectively, and whereas samples without novel alleles at any one of those loci were assigned MSS.

Statistical analysis
--------------------

The JMP 10.0 (SAS Institute Inc., Cary, NC) software package was used for data analyses. Survival curves were generated using Kaplan-Meier method, with significance evaluated using the Mantel-Cox log-rank test. Risk ratio was calculated using the Cox proportional hazard model in both univariate and multivariate analyses. Values of p \< 0.05 were considered statistically significant.

Results
=======

Clinico-pathologic data
-----------------------

The characteristics of the 770 CRC patients are described earlier \[[@B18]\]. The median age at the time of surgery was 57 years (inter quartile range \[IQR\], 47.7 -68.0 years). The 5 year overall survival of our study population was 70.6%.

*BRAF* mutation and their clinico-pathological correlation
----------------------------------------------------------

Seven hundred fifty seven colorectal cancer cases were analyzed for *BRAF* mutations and the remaining 13 cases were not interpretable due to insufficient amount of DNA and other technical reasons. Of the 757 cases analyzed for *BRAF* status, *BRAF* mutations were observed in nineteen cases and the incidence of *BRAF* in Saudi colorectal cancer was 2.5%( 19/757) (Table  [2](#T2){ref-type="table"}). Surprisingly this is among the lowest incidence of *BRAF* mutations reported in literature (Tables  [3](#T3){ref-type="table"} and [4](#T4){ref-type="table"}). Of these 19 CRC with *BRAF* mutations, 17 were seen in the V600E type and the other 2 were seen in V594G and V601E (Table  [3](#T3){ref-type="table"} and Figure  [1](#F1){ref-type="fig"}). To reconfirm these results and rule out the fact that we were missing any *BRAF* mutations due to tumor heterogeneity issues, cancer tissue was re-punched from 2-3 different tumor areas and *BRAF* analysis was repeated on 400 of these 757 samples. Repeat Sanger sequencing did not show any discordance with earlier results and failed to reveal any new cases with *BRAF* mutation. As shown in Table  [2](#T2){ref-type="table"}, CRC with *BRAF* mutations were significantly associated with right sided tumors (p = 0.0019), microsatellite instable MSI-H status (p = 0.0144) and CIMP high phenotype (p = 00017). Of the 19 cases with *BRAF* mutation, MSI-H, MSI-L and MSS were 6 cases (31.6%), 5 cases (26.3%) and 8(42.1%) cases respectively. The degree of Ki-67 staining as a measure of proliferative index was significantly higher in the *BRAF* mutation positive CRC group (88.89 ± 12.78) as compared to the *BRAF* mutation negative group (80.60 ± 25.30, p = 0.0162; Students T test; Additional file [1](#S1){ref-type="supplementary-material"}: Figure S1). A statistical trend was noted with presence of *BRAF* mutation and older age (age \> 50; p = 0.0938) and a mutual exclusivity was observed with *KRAS* mutations (p = 0.0518; a statistical trend was noted). *BRAF* mutations were not associated with gender, histology subtype, tumor differentiation and Stage.

###### 

**Correlation of*BRAF*Mutation with clinico-pathological parameters in colorectal carcinoma**

                               **Total**   **Positive**   **Negative**   **P value**               
  --------------------------- ----------- -------------- -------------- ------------- ----- ------ --------
  **Total number of cases**       757                          19            2.5       738   97.5      
  **Age**                                                                                              
    \< 50 years                   246          32.5            3             1.2       243   98.8   0.0938
    \> 50 years                   511          67.5            16            3.1       495   97.9      
  **Sex**                                                                                              
    Male                          394          52.0            11            2.8       383   97.2   0.6044
    Female                        363          48.0            8             2.2       355   97.8      
  **Tumour site\***                                                                                    
    Left colon                    600          83.0            10            1.7       590   98.3   0.0019
    Right colon                   123          17.0            9             7.3       114   92.7      
  **Histological type**                                                                                
    Adenocarcinoma                673          88.9            18            2.7       655   97.3   0.3673
    Mucinous Carcinoma            84           11.1            1             1.2       83    98.8      
  **Tumour stage\***                                                                                   
    I                             88           12.2            4             4.6       84    95.4   0.6853
    II                            255          35.3            7             2.7       248   97.3      
    III                           289          40.0            6             2.1       283   97.9      
    IV                            90           12.5            2             2.2       88    97.8      
  **Differentiation**                                                                                  
    Well                          74           9.8             2             2.7       72    97.3   0.8887
    Moderate                      590          77.9            14            2.4       576   97.6      
    Poor                          93           12.3            3             3.2       90    96.8      
  **MSI-Molecular\***                                                                                  
    MSI-H                         81           11.1            6             7.4       75    92.6   0.0144
    MSI-S/L                       651          88.9            13            2.0       638   98.0      
  ***KRAS*Mutation\***                                                                                 
    Positive                      216          28.7            2             0.9       214   99.1   0.0518
    Negative                      537          71.3            17            3.2       520   96.8      
  **CIMP\***                                                                                           
    High                          24           5.1             4            16.7       20    83.3   0.0017
    Low & middle                  444          94.9            8             1.8       436   98.2      

\*Data were not available (NA) for some cases for tumor site (NA = 34), Stage (NA = 35), MSI-Molecular (NA = 25), *KRAS* Mutation (NA = 4), and CIMP (NA = 289).

###### 

**Clinical information, pathologic diagnosis,*BRAF*and*KRAS*testing results**

     **Case \#**      **AGE**   **Gender**   **Histology Type**      **Site**       **Grade**   **Stage**   ***BRAF***   ***KRAS***   **CIMP**    **MSI-PCR**       **Pre-existing**
  ------------------ --------- ------------ -------------------- ----------------- ----------- ----------- ------------ ------------ ----------- ------------- --------------------------
       *BRAF*-1         60         Male              AC               Caecum            2           I         V601E       Codon 13    Low CIMP       MSI-L          Tubular adenoma
       *BRAF*-2         47         Male              AC           Ascending colon       2           I         V600E       Codon 13       NA          MSI-S         Hyperplastic polyp
   SERRATED ADENOMA                                                                                                                                            
       *BRAF*-3         71        Female             AC              Rt colon           1          III        V600E          WT          NA          MSI-H         Unremarkablemucosa
       *BRAF*-4         57        Female             AC              Rt colon           3          IV         V600E          WT       Low CIMP       MSI-S         Unremarkablemucosa
       *BRAF*-5         67         Male              AC            Recto sigmoid        2          II         V600E          WT       Low CIMP       MSI-S         Unremarkablemucosa
       *BRAF*-6         74        Female             AC              Rt colon           3          II         V600E          WT       Low CIMP       MSI-H         Unremarkablemucosa
       *BRAF*-7         66         Male              AC           Ascending colon       2          III        V594G          WT       Low CIMP       MSI-L              Adenoma
       *BRAF*-8         68         Male              AC              Rt colon           2          IV         V600E          WT       Low CIMP       MSI-S        Unremarkablemucosa.
       *BRAF*-9         61        Female             AC              Rt colon           1           I         V600E          WT       High CIMP      MSI-H      Small hyperplasticpolyps
      *BRAF*-10         46         Male              AC               Sigmoid           2           I         V600E          WT          NA          MSI-L         Hyperplastic polyp
      *BRAF*-11         34         Male              AC            Recto sigmoid        2          III        V600E          WT       Low CIMP       MSI-S         Unremarkablemucosa
      *BRAF*-12         71         Male              AC               Sigmoid           2          III        V600E          WT          NA          MSI-S         Hyperplastic polyp
      *BRAF*-13         59         Male              AC               Rectal            2          III        V600E          WT       High CIMP      MSI-S          Tubular adenoma
      *BRAF*-14         66        Female             AC              Rt colon           2          II         V600E          WT          NA          MSI-H        Unremarkable mucosa
      *BRAF*-15         66         Male              AC            Sigmoid colon        2          II         V600E          WT       Low CIMP       MSI-S       No colonic mucosa seen
      *BRAF*-16         73        Female             AC              Rt colon           3          II         V600E          WT       High CIMP      MSI-H        Unremarkable mucosa
      *BRAF*-17         72         Male              AC              Rt colon           2          II         V600E          WT       High CIMP      MSI-H        Unremarkable mucosa
      *BRAF*-18         74        Female             AC            Sigmoid colon        2          II         V600E          WT          NA          MSI-L        Unremarkable mucosa
      *BRAF*-19         55        Female             MC            Recto sigmoid        2          III        V600E          WT          NA          MSI-L        Unremarkable mucosa

###### 

**Summary of previous studies on*BRAF*mutation in colorectal carcinoma**

             **Study**             **Country**   **% with*BRAF***   ***BRAF*mutation detected**  **Methods of mutation detection**
  ------------------------------- ------------- ------------------ ----------------------------- --------------------------------------------------------------------------------------------------------------------------------------
        **Li-Ling H, 2012**          Taiwan            1.1                     2/182             High-resolution melting point (HRM) polymerase chain reaction (PCR) for *BRAF* V600E mutations
          **Li H , 2011**             China             7                     14/200             Sequenced by Pyrosequencer PyroMark ID system-Exon 15, V600E
         **Liou J, 2011**             China            3.8                    12/314             Sequencing of exons 11 and 15
        **Yokota T, 2011**            Japan            4.7                    15/319             Cycleave PCR technique for V600E mutation
       **Nakanishi R, 2012**          Japan            6.7                    17/254             *BRAF* pyrokit pyrosequencing
        **Ajay Goel, 2009**          Israel            18.7                   24/128             Direct sequencing using the BigDye version 1.1 cycle-sequencing kit
         **Rozek L, 2010**           Israel             5                     65/1300            Direct sequencing of exon 15 of *BRAF*
         **Price T, 2011**          Australia          10.6                   33/315             High-resolution melting point (HRM) polymerase chain reaction (PCR) for *BRAF* V600E mutations
         **Tran B, 2011**           Australia           11                    57/524             Mutation-specific real-time polymerase chain reaction assay.
     **Di Nicolantonio, 2008**        Italy             10                    11/113             Automated sequencing by ABI PRISM 3730 exon15
        **Richman S, 2009**            UK              7.9                    422/711            Pyrosequenced on a PyroMark ID system (Biotage AB) Codon 600
         **Roth A, 2009**          Switzerland         7.9                   103/1307            Allelic discrimination assay on a 7500 real-time polymerase chain reaction for V600E
        **Zlobec I, 2010**         Switzerland          12                    45/374             *BRAF* (exon 15 codon 600) direct sequencing of single-stranded PCR products using the BigDyeVR Terminator v1.1 cycle sequencing kit
   **Farina-Sarasqueta A, 2010**   Netherlands         19.8                   59/297             V600E mutation on the *BRAF* gene by real-time PCRLight Cycler v2.0 (Roche)
       **Saridaki Z, 2010**          Greece            8.3                    12/144             Real-time PCR using the allelic discrimination method with ABI PRISM 7900 T Sequence Detection System
        **Modest D, 2012**           Germany           11.6                   17/146             Exons 11 and 15 of the *BRAF*pyro-sequencing
       **Samowitz W, 2005**            USA             9.5                    87/911             Sequencing in both directions
        **Shaukat A,2010**             USA             21.8                   36/165             *BRAF* V600E mutation -Mutector II *BRAF*/Ras mutation detection panel assay kit
         **Kalady M,2012**             USA              12                    56/475             Direct sequencing
         **Ogino S,2012**              USA              15                     11/75             c.1799 T \> A (p.V600E) mutation

![**Example of*BRAF*gene mutations in CRC.** Sequencing traces of cases harboring wild type **(A)**, and V600E **(B)**, D594G **(C)** and K601E **(D)** mutations, respectively.](1476-4598-13-168-1){#F1}

All the pathology reports of colonic biopsies and resection specimens and slides were reviewed to ascertain the presence of serrated adenomas in the 19 cases with *BRAF* mutations. We confirmed the presence of a serrated adenoma in only 1 case; hyperplastic polyps in 3 cases; tubular adenomas in 2 and the remaining 13 cases showed unremarkable colorectal mucosa.

*KRAS* mutation and their clinico-pathological correlation
----------------------------------------------------------

In our series of 770 CRC samples 755 were analyzable for *KRAS* mutations and the incidence of *KRAS* mutations was 28.6% (216/755; Additional file [2](#S2){ref-type="supplementary-material"}: Table S1). The remaining 15 samples of the 770 CRC could not be analyzed due to insufficient DNA or technical reasons. Most of *KRAS*-mutated cases showed a mutation at codon 12.

(152 cases; 70.3%) and codon 13 (64 cases; 29.7%). *KRAS* mutations were associated with right-sided CRC (p = 0.0064).

Co-existence of *KRAS* and *BRAF* mutation
------------------------------------------

The clinico-pathological and molecular characteristics of the two CRC cases with co-existence of *KRAS* and *BRAF* mutations - "*BRAF*-1" and "*BRAF*-2" are summarized in Table  [3](#T3){ref-type="table"}. Both the patients were males with age \> 40 years(47 years and 60 years); MSI-L/MSS type; histology subtype of adenocarcinomas with moderate differentiation; and Stage I cancer. Both these cases had mutation in codon 13 for *KRAS* gene and the *BRAF* gene showed mutation at V600E and V601E for *BRAF*-1 and *BRAF*-2 specimen respectively.

Microsatellite instability analysis
-----------------------------------

MSI analysis data was available in 741 of the 770 samples and the incidence of microsatellite instable (MSI-H), microsatellite low (MSI-L) and microsatellite stable (MSS) was 11.2%( 83/741), 18.6% (138/741) and 70.2% ( 520/741) respectively. The remaining 29 samples could not be analyzed due to insufficient DNA, lack of paired normal DNA or technical reasons.

*BRAF* mutation, *KRAS* mutation, and overall survival
------------------------------------------------------

The prognostic significance of *KRAS* and *BRAF* mutation was analyzed with the use of the Kaplan--Meier method. Patients with *KRAS* mutation had poorer survival as compared to CRC with wild type *KRAS* gene (p = 0.0078) (Figure  [2](#F2){ref-type="fig"}A). In the multivariate analysis using the Cox proportional hazard model (Additional file [3](#S3){ref-type="supplementary-material"}: Table S2) for multiple factors such as age, gender, AJCC stage, microsatellite instability and tumor differentiation, the relative risk was 1.75 for CRC with *KRAS* mutation(95% CI 1.26-2.42; p = 0.0011) and 6.70 for advanced AJCC stage(95% CI 4.78-9.31; p ≤ 0.0001). Thus, *KRAS* mutation was an independent prognostic marker for poor survival in CRC across all stages. We also assessed the overall survival of *KRAS* mutation at codon12 and codon13. Amongst the *KRAS*-mutated cases, mutation in codon 12 was associated with the worst survival (62.8%; *p* = 0*.*0230) compared with codon 13 mutations (64.7%) or absence of *KRAS* mutations (73.5%). *BRAF* mutation was not associated with any prognostic significance (p = 0.3310; Figure  [2](#F2){ref-type="fig"}B).

![**Impact of*KRAS*and*BRAF*mutations in CRC and the Kaplan--Meier.** Survival analysis. **(A)** Colorectal cancer patients with *KRAS* mutations had reduced overall survival of 63.5% at 5 years compared with 73.5% without *KRAS* mutations (p = 0.0078). **(B)** In CRC patients, there was no significance in survival between *BRAF* mutated and non mutated cases. (p = 0.3310).](1476-4598-13-168-2){#F2}

Discussion
==========

Accumulating evidence implicates *BRAF* mutations to have diagnostic, therapeutic and prognostic significance in CRC \[[@B10],[@B19]-[@B22]\]. In our study, the *BRAF*-V600E mutation was identified in only 2.5% of all CRC, which is significantly lower than earlier reports of *BRAF* mutation in CRC worldwide (5-15%; \[[@B22]-[@B26]\]). The overall low frequency of the *BRAF*-V600E mutation and serrated adenomas in this unique ethnic group of Saudi colorectal cancer cases suggests a very small role of the *BRAF* gene in the development of CRC and raises some interesting future questions on the burden of familial colorectal cancers like Hereditary non polyposis colorectal cancer cancer(HNPCC) syndrome in Saudi Arabia.

The reported frequency of *BRAF* mutations in different populations varies widely from a low incidence of 1% in Taiwan to 19.8% and 21.8% in Netherlands and USA respectively \[[@B22]-[@B25],[@B27]-[@B40]\]. A lower frequency has been observed in most of the Asian population as is evident from the lowest *BRAF* mutation incidence of 1% in Taiwan where *BRAF* mutation was seen in 2/182 CRC. A similar low incidence was seen in China (3.8% and 7%) and Japan (4.7% and 6.7%). *BRAF* mutation was also observed at a lower rate of 5% in Israel \[[@B39]\]. Interestingly the frequency of the *BRAF* V600E mutation varies widely between population groups, both within single studies (5.8% in the Ashkenazi versus 3.2% in the non-Ashkenazi) and also between reports from different groups but within the same region/country \[[@B36],[@B41]\]. The lower incidence of *BRAF* mutations in Saudi CRC patients could be due to a different ethnic populations with varied underlying genetic predisposition to *BRAF*-mutated tumors, role of environmental influences like diet, smoking and other unknown factors. Different methods used to detect gene mutation such as 454 next generation sequencing, Sanger sequencing, pyrosequencing and melting curve analysis also influence the detection rate of a gene mutation \[[@B42]\]. An earlier study has highlighted the differing rates of *BRAF* mutation in distinct ancestral populations with a lower frequency observed in Asian population as compared to White and Black patients in their study \[[@B43]\].

Although *BRAF* mutations occur early in colorectal carcinogenesis and have been observed in colorectal adenomas, tumor progression needs additional acquired DNA microsatellite instability caused by hypermethylation of *MLH1* in the setting of the CpG island methylator phenotype (CIMP) \[[@B12],[@B44]\]. These precursor lesions that harbor *BRAF* mutation, microsatellite instability and CIMP phenotype have a distinct morphology and are termed serrated adenomas. A retrospective review of all the available biopsies of hyperplastic polyps and adenomas biopsies confirmed the presence of only one case that had a morphology consistent with serrated adenomas. Additional efforts to identify serrated adenomas from the FFPE archives of Department of Pathology confirmed the fact that serrated adenomas were exceedingly rare. We have analyzed CIMP in 500 CRC patients and have observed a very low frequency of CIMP of 4.8% (data not shown). In concordance with an earlier study we hypothesize that lack of a propensity for hypermethylation and other factors in Saudi CRC prevents the driver *BRAF* mutation in premalignant lesions to progress to full blown cancers \[[@B13]\]. Although smoking is one of the factors implicated in CIMP phenotype and the incidence of smoking in Saudi Arabia is quite high \[[@B45],[@B46]\], the prevalence of *BRAF* mutations, CIMP and serrated adenomas in our study population was on the lower side. Moreover, the significantly lower incidence of *BRAF* mutations in our study suggests the existence of a possibly higher number of familial syndromes like HNPCC that are characterized by a virtual lack of *BRAF* abnormalities in colorectal cancers. A study is being conducted to determine the true incidence of HNPCC in Saudi Arabia. Presence of *BRAF* V600E mutation in CRC tumors that lacks the expression of MLH1 by IHC does not warrant further genetic testing and excludes the possibility of the presence of a germline mutation in mismatch repair (MMR) genes. This exquisite sensitivity of *BRAF* V600E somatic mutation for sporadic MSI has led to the development of an algorithm for screening of LS as a multistep diagnostic approach in several guidelines and recommendations \[[@B15],[@B47]\]. Since a significant proportion of sporadic CRC get excluded, the use of *BRAF* V600E as a screening tool to identify sporadic MSI CRC tumors is highly cost effective \[[@B15],[@B47],[@B48]\]. Newer developments in the detection of *BRAF* V600E mutation in CRC by IHC have shown to have a comparable sensitivity and specificity as PCR testing \[[@B49]\]. After stringent validation of *BRAF* IHC in each lab, *BRAF* testing by IHC will prove to be a simple, economical, labor and time saving test that can be performed even in small biopsies that yield a small amount of DNA. Finally Weisenberger et al investigated CIMP in CRC and demonstrated that MSI-H CRC are either HNPCC or MSI-H and CIMP + with or without MLH1 methylation \[[@B50]\]. The authors concluded that CIMP + encompass almost all sporadic MSI-H CRC while MLH1 methylation constitute a part of, but not all CIMP + CRC tumors. Since *BRAF* mutations distinctly correlate with CIMP + CRC, *BRAF* testing could outperform MLH1 methylation in identifying sporadic MSI-H CRC tumors in the diagnostic approach of LS \[[@B50]\].

Emerging studies highlight the critical significance of the impact of *BRAF* mutations on colorectal research. Although there has been remarkable success in using *BRAF* inhibitors in melanomas with a response rate of over 80%, a lower response rate of about 10% is seen in CRCs \[[@B20]\]. A key mechanism causing resistance to *BRAF* inhibitors in CRC is upregulation of the EGFR pathway and a combination therapy with EGFR inhibitors and *BRAF* inhibitors might prove effective \[[@B20]\]. Dual synergism could guide strategies that aim to improve outcomes especially in patients who are refractory to initial lines of therapy.

In conclusion, we observed a very low incidence of CRC with *BRAF* mutations that showed a significant association with right sided tumors, CIMP high phenotype and microsatellite instability. Future work would be directed to establish an effective screening program to study the prevalence of HNPCC cases in Saudi Arabia and also try to understand the complex interaction between genetics and environmental factors that contribute to this low incidence of *BRAF* mutations in this region.
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*BRAF* mutation and proliferation index as measured by Ki-67 IHC expression. Box Plot charts indicates the mean and SD of Ki-67 expression in two groups: The expression of Ki-67 in *BRAF* Positive (88.89 ± 12.78) and *BRAF* Negative (80.60 ± 25.30, p value 0.0162).
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Univariate and Multivariate analysis of Kras Mutation using Cox Proportional Hazard Model.
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